These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Moujalled DM; Pomilio G; Ghiurau C; Ivey A; Salmon J; Rijal S; Macraild S; Zhang L; Teh TC; Tiong IS; Lan P; Chanrion M; Claperon A; Rocchetti F; Zichi A; Kraus-Berthier L; Wang Y; Halilovic E; Morris E; Colland F; Segal D; Huang D; Roberts AW; Maragno AL; Lessene G; Geneste O; Wei AH Leukemia; 2019 Apr; 33(4):905-917. PubMed ID: 30214012 [TBL] [Abstract][Full Text] [Related]
4. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models. Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420 [TBL] [Abstract][Full Text] [Related]
5. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo. Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744 [TBL] [Abstract][Full Text] [Related]
6. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells. Rahmani M; Nkwocha J; Hawkins E; Pei X; Parker RE; Kmieciak M; Leverson JD; Sampath D; Ferreira-Gonzalez A; Grant S Cancer Res; 2018 Jun; 78(11):3075-3086. PubMed ID: 29559471 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594 [TBL] [Abstract][Full Text] [Related]
8. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002 [TBL] [Abstract][Full Text] [Related]
9. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner. Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423 [TBL] [Abstract][Full Text] [Related]
10. Apoptosis targeted therapies in acute myeloid leukemia: an update. Ball S; Borthakur G Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684 [No Abstract] [Full Text] [Related]
11. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells. Nechiporuk T; Kurtz SE; Nikolova O; Liu T; Jones CL; D'Alessandro A; Culp-Hill R; d'Almeida A; Joshi SK; Rosenberg M; Tognon CE; Danilov AV; Druker BJ; Chang BH; McWeeney SK; Tyner JW Cancer Discov; 2019 Jul; 9(7):910-925. PubMed ID: 31048320 [TBL] [Abstract][Full Text] [Related]
12. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML. Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848 [TBL] [Abstract][Full Text] [Related]
13. Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance. Liu F; Zhao Q; Su Y; Lv J; Gai Y; Liu S; Lin H; Wang Y; Wang G Exp Hematol; 2022 Jan; 105():39-49. PubMed ID: 34767916 [TBL] [Abstract][Full Text] [Related]
14. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models. Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715 [TBL] [Abstract][Full Text] [Related]
15. Potential mechanisms of resistance to venetoclax and strategies to circumvent it. Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response. Sharon D; Cathelin S; Mirali S; Di Trani JM; Yanofsky DJ; Keon KA; Rubinstein JL; Schimmer AD; Ketela T; Chan SM Sci Transl Med; 2019 Oct; 11(516):. PubMed ID: 31666400 [TBL] [Abstract][Full Text] [Related]
17. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leonard JT; Rowley JS; Eide CA; Traer E; Hayes-Lattin B; Loriaux M; Spurgeon SE; Druker BJ; Tyner JW; Chang BH Sci Transl Med; 2016 Aug; 8(354):354ra114. PubMed ID: 27582059 [TBL] [Abstract][Full Text] [Related]
18. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. Ten Hacken E; Valentin R; Regis FFD; Sun J; Yin S; Werner L; Deng J; Gruber M; Wong J; Zheng M; Gill AL; Seiler M; Smith P; Thomas M; Buonamici S; Ghia EM; Kim E; Rassenti LZ; Burger JA; Kipps TJ; Meyerson ML; Bachireddy P; Wang L; Reed R; Neuberg D; Carrasco RD; Brooks AN; Letai A; Davids MS; Wu CJ JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282833 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Zhao J; Niu X; Li X; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Ge Y Oncotarget; 2016 Jun; 7(23):34785-99. PubMed ID: 27166183 [TBL] [Abstract][Full Text] [Related]